US FDA approves Alnylam's Oxlumo to treat primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients

Press/Media

Period26 Nov 2020

Media coverage

1

Media coverage

  • TitleUS FDA approves Alnylam's Oxlumo to treat primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients
    Media name/outletPharmaBiz
    Country/TerritoryIndia
    Date26/11/20
    PersonsJeffrey Saland
View all 1
View less